By using different lupus mouse models, such as (NZBxNZW)F1 mice, BXSB.DTR mice or Tlr7.Tg animals, it has been seen that depletion of pDCs ameliorates SLE manifestations and inflammation, suggesting that targeting the function or accumulation of pDCs in tissues could be a viable therapy to ameliorate SLE (66–68). Here, TLR7 is linked to systemic lupus erythematosus.